Administration of ibrutinib beginning 2 weeks prior to leukapheresis and continuing until 3 months after CD19-specific chimeric antigen receptor T-cell therapy appeared well tolerated among patients with relapsed or refractory chronic lymphocytic leukemia, according to retrospective study results presented at ASH Annual Meeting and Exposition.
Ibrutinib plus CD19-specific CAR T-cell therap... - CLL Support
Ibrutinib plus CD19-specific CAR T-cell therapy may benefit patients with relapsed or refractory CLL
Written by
wmay13241
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
pkguk2PartnerCLL Support Association
Interesting research. Hopefully this will make CAR-T more tolerable to patients, and with fewer side-effects.
Not what you're looking for?
You may also like...
More CAR-T: Looking Back to Go Forward in CAR-T Cell Therapy in R/R CLL
Long-term data from a phase 1 study investigating anti-CD19 chimeric antigen receptor (CAR) T-cell...
Axi-Cel (anti-CD19 CAR T-cell therapy FMC63-28Z) Induces Durable Remissions in Relapsed CLL, B-Cell Lymphoma
Patients with relapsed chronic lymphocytic leukemia (CLL) and B-cell lymphoma who received the...
An Early Look at When CAR-T Therapy Fails Patients With CLL
Not exactly an optimistic report.
Dr James Gerson, MD, - "Not a lot is known as to what happens in...
Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Overall response rates were 95% (treatment-naïve) and 92% (relapsed/refractory). Thirty-two percent...
Related Posts
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL- Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL- The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden
